New rapid test could speed up sepsis diagnosis in ER

NCT ID NCT01904188

Recruiting now Knowledge-focused Sponsor: Michigan State University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new rapid diagnostic device called In-Dx to quickly identify infections and antibiotic resistance in emergency patients with suspected sepsis. Researchers will compare the device's results to standard lab cultures using stored samples from 2,500 patients. The goal is to see if the device can provide accurate results faster, but it will not affect current patient care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: In-Dx rapid diagnostic device
What this could lead to: If successful, this could lead to faster, more accurate identification of infections and antibiotic resistance, potentially improving sepsis treatment.
What could go wrong: This is an early-stage diagnostic study that does not change patient care yet. The device may not be accurate enough or may not work in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIBIOTIC RESISTANCE GENES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease coinfection Coronavinae infectious disease fungal infectious disease infectious disease infectious disease with sepsis Orthocoronavirinae infectious disease Sepsis Systemic Inflammatory Response Syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIBIOTIC RESISTANCE GENES HUMAN GENOME ANALYSIS INFECTION MIXED INFECTION, BACTERIAL INFECTION, CORONAVIRUS INFECTION, FUNGAL SEPSIS SYSTEMIC INFLAMMATORY RESPONSE SYNDROME

Contacts and locations

Locations

McLaren Greater Lansing
RECRUITING

Lansing, Michigan, 48910, United States
University of Michigan Health/Sparrow (name change only)
RECRUITING

Lansing, Michigan, 48909, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.